Role of the Nasal Environment in Obesity
Launched by KATHARINA TIMPER · Nov 29, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the nasal environment in people who are obese compared to those who are lean. The goal is to understand how the nasal area might play a role in obesity and help improve treatments for those who struggle with weight issues. The study is currently recruiting participants, and they are looking for adults between the ages of 18 and 55 who meet certain criteria related to their body weight. Specifically, they need 50 participants with obesity (a body mass index, or BMI, over 30), 50 lean participants (BMI between 18 and 25), and 50 obese patients who are scheduled for weight loss surgery (BMI over 35).
To participate, individuals must provide written consent and meet the age and BMI requirements. However, there are some exclusions, such as smokers, those with certain sinus issues, or individuals with severe chronic diseases. Participants can expect to undergo assessments related to their nasal environment, which may include simple tests and questionnaires. The information gathered may help researchers better understand the relationship between nasal health and obesity, potentially leading to new ways to support weight management in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • N=50 adult male and female patients with obesity will be included in this study.
- Inclusion criteria:
- Inclusion criteria:
- • Age 18-55 years
- • Written informed consent
- • BMI \> 30 kg/m2
- • N=50 adult lean patients age- and sex-matched to the group of obese patients will be included in this study.
- Inclusion criteria:
- • Age 18-55 years
- • Written informed consent
- • BMI 18-25 kg/m2
- • N=50 adult male and female patients with obesity with scheduled bariatric will be included in this study
- Inclusion criteria:
- • Age 18-55 years
- • Written informed consent
- • BMI \> 35 kg/m2
- Exclusion Criteria:
- • Smoking
- • Chronic or acute sinusitis
- • Surgical intervention of the nasal cavity or the paranasal sinus
- • Use of antibiotics within the last 31 days18
- • Current illicit drug abuse including daily marijuana or CBD consumption (≤ 24 g of alcohol per day allowed)
- • Any kind of severe chronic disease (e.g. severe heart failure, active cancer disease)
- • Use of any kind of decongestant more than twice a week
- • Use of cortisone-containing nasal spray within the last 3 months
- • Acute allergic rhinitis
- • History of neurodegenerative diseases
- • History of severe head trauma
- • Severe renal impairment (e.g. estimated glomerular filtration rate \<30 ml/min/m2)
About Katharina Timper
Katharina Timper is a dedicated clinical trial sponsor with a robust commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and treatments, Ms. Timper leads initiatives that prioritize ethical standards and regulatory compliance, ensuring the integrity of clinical trials. Her expertise encompasses a wide range of therapeutic areas, and she collaborates closely with healthcare professionals, research institutions, and regulatory bodies to facilitate the successful execution of trials. Driven by a passion for scientific excellence, Katharina Timper is committed to fostering partnerships that enhance the development of safe and effective medical interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Trial Officials
Katharina Timper, Prof. Dr. med.
Principal Investigator
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported